Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects

British Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2008, Pages 848-854

  Kim, Bo Hyung ^a   Lim, Hyeong Seok ^b   Chung, Jae Yong ^a   Kim, Jung Ryul ^a   Lim, Kyoung Soo ^a   Sohn, Dong Ryul ^c   Cho, Joo Youn ^a   Yu, Kyung Sang ^a   Shin, Sang Goo ^a   Paick, Jae Seung ^a   Jang, In Jin ^a  

^a Seoul National University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Pharmacokinetics; Phosphodiesterase type 5 inhibitor; Safety; Udenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; UDENAFIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BLOOD SAMPLING; BLURRED VISION; CLINICAL LABORATORY; CLINICAL TRIAL; COLOR DISCRIMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ECTOPIC ATRIAL RHYTHM; ERYEBALL PAIN; EYE PAIN; FACIAL FLUSHING; FATIGUE; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INDIGESTION; KOREA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NORMAL HUMAN; NOSE STUFFINESS; P AXIS DEVIATION; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TINGLING; URINALYSIS; WATERY STOOL;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; KOREA; MALE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINES;

EID: 43549087078     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03107.x     Document Type: Article

References (20)

1. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt T. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006 166: 207 12.
2. Lue TF. Erectile dysfunction. N Engl J Med 2000 342: 1802 13.
3. Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 1997 15: 32 5.
4. Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. In: Campbell-Walsh Urology, 9th edn, eds Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. China: Saunders, 2007 728 9.
5. Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002 162: 1349 60.
6. Raja SG, Nayak SH. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 2004 78: 1496 506.
7. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005 334: 930 8.
8. Vardi Y, Klein L, Nassar S, Sprecher E, Gruenwald I. Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology 2002 59: 747 52.
9. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999 83: 21C 8C.
10. Viagra® (sildenafil citrate) prescribing information; Description, clinical pharmacology, adverse reactions. Pfizer Laboratories 2007. Available at: http://fda.gov/cder/foi/label/2007/0208955027161.pdf (last accessed: 27 February 2008).
11. Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB. Mechanism of erectogenic effect of the selective phosphodieterease type 5 inhihbitor, DA-8159. Arch Pharm Res 2002 25: 873 8.
12. Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Invest Drugs 2006 7: 661 9.
13. Shim HJ, Lee EJ, Jung YH, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal 2002 30: 527 33.
14. Cho JY, Lim HS, Yu KS, Shim HJ, Jang IJ, Shin SG. Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase inhibitor, DA-8159, in human plasma and urine. J Chromatogr B Anal Technol Biomed Life Sci 2003 795: 179 86.
15. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002 53: 5S 12S.
16. Klotz T, Sachse R, Heidrich A, Jockenhövel F, Rohde G, Wensing G, Horstmann R, Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001 19: 32 9.
17. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005 5: 447 58.
18. Shim HJ, Kim YC, Park KJ, Kim DS, Kwon JW, Kim WB, Lee MG. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci 2003 92: 2185 95.
19. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999 29: 297 310.
20. Dong-A Research Laboratories. Zydena® (udenafil), Investigator's brochure. August 2007.